Jazz Pharmaceuticals (JAZZ) Stock
Sleep and cancer drug maker with rare disease focus. Here's the price, business snapshot, and what's worth knowing about Jazz Pharmaceuticals in June 2026.
Jazz Pharmaceuticals plc (JAZZ) is a mid‑cap biopharmaceutical company (market cap about $8.34B) known for marketed therapies in sleep disorders, oncology and rare disease. Investors often watch Jazz for its mix of established revenue-generating products and a pipeline that includes both internal programmes and in‑licenced assets. The company’s strategy blends product lifecycle management, targeted acquisitions and clinical development to broaden indications and grow sales. Key considerations include revenue concentration from a few core products, ongoing R&D spend, regulatory risk tied to clinical outcomes and the potential benefits of successful label expansions. Financially, Jazz’s performance can be sensitive to trial results, patent expiries and competitive entrants. This summary is educational only: values can rise and fall, past performance is not indicative of future results, and this is not personalised investment advice. Investors should consider their own risk tolerance and seek independent financial advice if unsure about suitability.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Jazz Pharmaceuticals' stock, believing it has the potential to rise further.
Financial Health
Jazz Pharmaceuticals is performing well with strong profits and cash flow, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring JAZZ
M&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: 2 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline and R&D
Jazz’s clinical pipeline and label-expansion efforts can drive future growth, though clinical setbacks and regulatory hurdles remain possible.
Product Concentration
A handful of products contribute a large share of revenue; successful diversification could reduce risk, while patent loss or competition could weigh on sales.
Strategic Growth Moves
Management pursues acquisitions and in‑licencing to expand indications and markets, a potentially positive route that also carries integration and execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
